Clinical trials have demonstrated that CXCR4 antagonists enhance the efficacy of immunotherapy in cancers by reducing regulatory T (Treg) cells, elucidating how certain mechanisms of CXCR4 in affecting Treg cells are essential for developing immunotherapeutic strategies.
ORGANISM(S): Homo Sapiens
